Capecitabine and temozolomide in advanced neuroendocrine neoplasms – A single center experience

#3572

Introduction: Neuroendocrine neoplasms (NENs) are heterogeneous malignancies, with a great variability in clinical behaviour and prognosis. Capecitabine and temozolomide combination (CAPTEM) has shown positive results in these patients, with a good safety profile.

Aim(s): The aim of our study was to evaluate the response, identify factors associated with worse prognosis and evaluate the occurrence of toxicities.

Materials and methods: We conducted a retrospective study of all patients with advanced NENs seen at our institution, who received treatment with CAPTEM between January 2010 and August 2021. The clinical variables and survival data were collected and analysed with SPSS®.

Conference:

Presenting Author:

Authors: Monteiro J, Caetano A, Pires M, Costa C, Elvas A,

Keywords: neuroendocrine neoplasm, neuroendocrine tumor, treatment, capecitabine, temozolomide, capecitabine and temozolomide, CAPTEM,